摘要
目的评估高病毒载量的HBeAg阳性慢性乙型肝炎(CHB)的抗病毒治疗效果。方法采用前瞻性、多中心、非随机、开放的研究方法,将120例高病毒载量的HBeAg阳性的入选病例均分为三组,分别采用恩替卡韦(ETV,A组)、聚乙二醇干扰素α-2a(PegIFNα-2a,B组)和两者联合应用(C组)治疗48周。分别在治疗24、48周及随访24周时进行疗效观察及安全性评估。结果在治疗48周及停药随访24周时,C组的病毒学应答疗效和HBeAg血清学应答均优于A、B组(P<0.05、P<0.01)。在24周时,B、C组ALT恢复正常率高于A组(52.6%、56.4%vs.27.8%)(P<0.05)。结论联合应用PegIFNα-2a和ETV治疗高病毒载量的HBeAg阳性CHB患者的疗效优于单药治疗。
Objective To evaluate the efficacy of antiviral therapy in HBeAg-positive chronic hepatitis B（CHB） patients with high level HBV. Methods With open non-randomized controlled multicenter clinical study, 120 HBeAg-positive patients with high level HBV were equally divided into three groups of A（treated with entecavir）, B（treated with pegylated interferon alpha-2a） and C （treated with both drugs）. The virological response （VR）, serological response （HBeAg, HBsAg clearance and seroconversion）, and biochemical response （BR） were tested at week 24 and 48 of therapy and week 24 of follow-up after the end of treatment （EOT） for evaluation of therapeutic effects and safety. Results At week 48 of treatment and week 24 of follow-up, the VR and serological response of HBeAg were better in group C than those in groups of A and B（P〈0. 05 and P〈0. 01）. At week 24 of follow-up after the end of treatment, the restoration rate of normal ALT was higher in groups of B and C than that in group A（52. 6% and 56. 4% vs. 27.8%） （P〈0. 05）. Conclusion Combined use of pegylated interferon alpha-2a and entecavir is better than using the one of both alone in treating CHB patients with high level HBV.
出处
《江苏医药》
CAS
北大核心
2014年第5期523-525,共3页
Jiangsu Medical Journal
基金
国家"十二五"科技重大专项子课题(2012ZX10002-004)
